Medication info
Nexial-D Tablet 20 mg (Esomeprazole Magnesium Trihydrate)

Nexial-D Tablet 20 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.25mg / 1 tablet
Manufacturer / importer
JW Pharmaceutical Corp.
Appearance
Pale pink round film-coated tablet
Packaging
28 tablets/box [(14 tablets/PTP x 2)]
Approval status
Active

MFDS item code 201507477 · Approved 2015.10.30 · Insurance code 644102810

Summary

Main use
Treatment of reflux and hyperacidity, Helicobacter- and NSAID-associated gastrointestinal disorders; prevention of ulcer rebleeding
Who uses it
Adults · Children
Adult dosage
1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric or duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting more than 4 weeks have not been conducted. 4) Patients requiring continued treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg daily. Doses greater than 80 mg daily should be divided into 2 doses per day. 6) Maintenance therapy following initiation of prevention of recurrent bleeding from gastric or duodenal ulcers by intravenous administration Administer 40 mg once daily for 4 weeks following initiation of prevention of recurrent bleeding from gastric or duodenal ulcers by intravenous administration. 4. Renal impairment: No dosage adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal failure. 5. Hepatic impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients: No dosage adjustment is necessary.
Children's dosage
2. Adolescents 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. 3. Children under 12 years: There is no experience with administering this medicine to children under 12 years.

Ingredients

Manufacturer
JW Pharmaceutical Corp.

Efficacy & effects

Treatment of reflux and hyperacidity, Helicobacter- and NSAID-associated gastrointestinal disorders; prevention of ulcer rebleeding

  • Gastroesophageal reflux disease
  • reflux esophagitis
  • esophagitis
  • Helicobacter pylori-positive duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease and reflux esophagitis. It is also used for long-term maintenance therapy to prevent recurrence in patients with esophagitis. Additionally, it is effective in treating and preventing recurrence of duodenal ulcers and peptic ulcers in patients with Helicobacter pylori infection. It is used for the treatment and prevention of ulcers related to gastrointestinal symptoms caused by nonsteroidal anti-inflammatory drugs. Furthermore, it is applied for maintenance therapy for Zollinger-Ellison syndrome and prevention of rebleeding from gastric or duodenal ulcers. Overall, it improves symptom relief and recurrence prevention of various digestive diseases.

Dosage and Administration

Adult dosage

1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric or duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting more than 4 weeks have not been conducted. 4) Patients requiring continued treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg daily. Doses greater than 80 mg daily should be divided into 2 doses per day. 6) Maintenance therapy following initiation of prevention of recurrent bleeding from gastric or duodenal ulcers by intravenous administration Administer 40 mg once daily for 4 weeks following initiation of prevention of recurrent bleeding from gastric or duodenal ulcers by intravenous administration. 4. Renal impairment: No dosage adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal failure. 5. Hepatic impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients: No dosage adjustment is necessary.

Children's dosage

2. Adolescents 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. 3. Children under 12 years: There is no experience with administering this medicine to children under 12 years.

Precautions

This medication should not be used in patients allergic to specific ingredients or benzimidazole compounds. Caution is needed when administering to patients with allergies to penicillin or macrolide antibiotics in combination therapy. This medication should not be administered to breastfeeding women, patients with a history of myocardial infarction, or patients taking certain antiviral medications. The medication contains a dye called Yellow No. 5, and individuals allergic to this ingredient should use it cautiously. Rarely, various side effects such as blood abnormalities, allergic reactions, hypomagnesemia, headache, dizziness, abdominal pain, skin rash may occur; if any symptoms occur, consult a doctor immediately. Long-term use requires regular testing to monitor for abnormalities. This medication suppresses gastric acid secretion and may increase the risk of bacterial overgrowth in the stomach; if diarrhea persists, inform the healthcare professional. Patients with osteoporosis or those on long-term treatment may have an increased risk of fractures and may require bone density testing. This medication may interact with other drugs, especially anticoagulants, antiviral medications, and anticonvulsants, so it is essential to inform healthcare providers if you are on these medications. Use during pregnancy is limited, and it is recommended not to take this medication while breastfeeding. In case of overdose, there is no specific antidote; seek appropriate treatment immediately at a medical institution, and keep it out of reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, mucositis, gastrointestinal candidiasis, microscopic colitis, elevated liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reactions with eosinophilia and systemic symptoms, fractures, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, substernal pain, facial edema, flushing, fatigue, influenza-like illness, generalized edema, leg edema, lethargy, pain, rigidity, peripheral edema, flushing, hypertension, tachycardia, thyroid swelling, irritable bowel syndrome, worsening constipation, dyspepsia, dysphagia, gastrointestinal malformation, upper abdominal pain, belching, esophageal dysfunction, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue swelling, ulcerative stomatitis, vomiting, earache, tinnitus, anemia, hypochromic anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver function abnormalities, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, polymyalgia rheumatica, arthralgia, loss of appetite, apathy, increased appetite, confusion, exacerbation of depression, hypertonia, anxiety, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremors, dizziness, visual field loss, paresthesia, drowsiness, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythematous rash, papular rash, angioedema, dermatitis, itching, urticaria, increased sweating, otitis media, altered sense of smell, taste loss, taste disturbance, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, frequency of urination, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundic polyps, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air and moisture. It is important to maintain the storage temperature between 1 to 30 degrees Celsius. Avoid storing in extremely hot or cold places.

Appearance and packaging

Appearance

Pale pink round film-coated tablet

Package unit

28 tablets/box [(14 tablets/PTP x 2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.